Agenus Inc.
https://agenusbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Agenus Inc.
Finance Watch: Venture Rounds Trend Toward The High End
Private Company Edition: First quarter data again confirm fewer but larger VC rounds in Q1. Big Q2 rounds include a $132.5m series C round for Endeavor Biomedicines, a $103m series A round for Reunion Neuroscience and Enlaza’s $100m series A.
Amgen Planning Pivotal Obesity Program For MariTide
Executives said during Amgen’s Q1 call that the company is “encouraged” by interim Phase II data for MariTide (AMG 133) in obesity, so it is designing Phase III trials and building manufacturing capacity.
Novartis Looks To Maintain A Lead In Radiopharmaceuticals With Mariana Takeout
The acquisition of Mariana will complement Novartis’s lutetium-based radioligand therapies with candidates using actinium. Lilly, Bristol and AstraZeneca all have made recent high-priced buys in the space.
Astellas Stakes Claim In CAR-Ts For Solid Tumors With Poseida Deal
Astellas is building off an existing relationship with the biotech formed last August, joining the growing number of large pharmas looking at tackling solid tumors with cell therapy.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Antigenics Inc. Aronex Pharmaceuticals AgenTus Therapeutics, Inc. Agenus Royalty Fund, LLC Agenus Switzerland Inc. Agenus UK Limited 4-Antibody
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice